Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1969 3
1972 1
1983 1
1984 1
1985 2
1986 2
1987 1
1988 3
1989 5
1990 5
1991 4
1992 5
1993 5
1994 7
1995 4
1996 5
1997 6
1998 4
1999 4
2000 4
2001 5
2002 4
2003 11
2004 5
2005 4
2006 8
2007 6
2008 3
2009 6
2010 10
2011 9
2012 9
2013 11
2014 9
2015 7
2016 10
2017 9
2018 10
2019 13
2020 8
2021 10
2022 12
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Among authors: van dongen g. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
The promise of immuno-PET in radioimmunotherapy.
Verel I, Visser GW, van Dongen GA. Verel I, et al. Among authors: van dongen ga. J Nucl Med. 2005 Jan;46 Suppl 1:164S-71S. J Nucl Med. 2005. PMID: 15653665 Free article. Review.
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles.
Rijcken CJF, De Lorenzi F, Biancacci I, Hanssen RGJM, Thewissen M, Hu Q, Atrafi F, Liskamp RMJ, Mathijssen RHJ, Miedema IHC, Menke-van der Houven van Oordt CW, van Dongen GAMS, Vugts DJ, Timmers M, Hennink WE, Lammers T. Rijcken CJF, et al. Among authors: van dongen gams. Adv Drug Deliv Rev. 2022 Dec;191:114613. doi: 10.1016/j.addr.2022.114613. Epub 2022 Nov 4. Adv Drug Deliv Rev. 2022. PMID: 36343757 Review.
Nanobodies in therapeutic applications.
Roovers RC, van Dongen GA, van Bergen en Henegouwen PM. Roovers RC, et al. Among authors: van dongen ga. Curr Opin Mol Ther. 2007 Aug;9(4):327-35. Curr Opin Mol Ther. 2007. PMID: 17694445 Review.
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.
Miedema IHC, Huisman MC, Zwezerijnen GJC, Grempler R, Pitarch AP, Thiele A, Hesse R, Elgadi M, Peltzer A, Vugts DJ, van Dongen GAMS, de Gruijl TD, Menke-van der Houven van Oordt CW, Bahce I. Miedema IHC, et al. Among authors: van dongen gams. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2068-2080. doi: 10.1007/s00259-023-06164-w. Epub 2023 Mar 2. Eur J Nucl Med Mol Imaging. 2023. PMID: 36859619 Free PMC article.
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
Slobbe P, Poot AJ, Windhorst AD, van Dongen GA. Slobbe P, et al. Among authors: van dongen ga. Drug Discov Today. 2012 Nov;17(21-22):1175-87. doi: 10.1016/j.drudis.2012.06.016. Epub 2012 Jul 2. Drug Discov Today. 2012. PMID: 22766374 Review.
242 results